Rivus Pharmaceuticals Closes $132 Million Series B Financing To Advance Hu6 For The Treatment Of Obesity And Cardio-Metabolic Disorders
Rivus Pharmaceuticals Closes $132 Million Series B Financing To Advance Hu6 For The Treatment Of Obesity And Cardio-Metabolic Disorders
09/22/22, 11:05 AM
Location
charlottesvilleMoney raised
$132 million
Industry
biotechnology
health care
Round Type
series b
Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. This financing will further support clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease.
Company Info
Location
mail 706 b forest street
charlottesville, virginia, united states
Additional Info
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). For more information please visit https://www.rivuspharma.com/